When patients develop a narrowing or blockage in the bile ducts, physicians must determine whether the cause is cancer or a benign condition. The location of these blockages adds challenges to the diagnosis, and this uncertainty can delay treatment decisions for patients in the event they have this rare type of cancer.
A team of researchers has developed BiliSeq, a molecular test that, according to recent research, detected bile duct cancer with twice the sensitivity of the standard test, giving physicians a more accurate picture of the patient’s diagnosis.
Findings published by Das et al in Gastroenterology describe the evaluation of BiliSeq’s real-world performance over 6 years in more than 2,000 patients across the United States, analyzing nearly 3,000 bile duct specimens. BiliSeq detected…